Pfizer's cancer portfolio 'underappreciated,' analyst says; Sanofi unveils new round of Toujeo research;

@FiercePharma: #ICYMI yesterday: AZ's Soriot lashes out at U.K.'s refusal to pay for first-in-class cancer drug. Article | Follow @FiercePharma

@EricPFierce: #FDA warning letter says Czech company shipped bacteria contaminated APIs to the US. Story | Follow @EricPFierce

@CarlyHFierce: Boehringer faces uphill battle for Stiolto, thanks to payer arm-twisting. More | Follow @CarlyHFierce

> Pfizer's ($PFE) oncology portfolio is "underappreciated," UBS said in a note to investors, citing the early success of its breast cancer drug Ibrance and in-development immuno-oncology meds. Report

> Sanofi ($SNY) announced plans for three follow-up studies on its new basal insulin, Toujeo, hoping real-world outcomes data will give it a marketing edge against its myriad rivals. Release

> Biogen ($BIIB) submitted its hemophilia drug Alprolix for approval in Europe, its partner Swedish Orphan Biovitrium said Thursday. Report

> Takeda's new Type 2 diabetes drug Zafatek, a DPP-4 inhibitor, is now available in the drugmaker's home country, Japan. Report

> AMAG Pharmaceuticals ($AMAG) brought on a new CMO, Dr. Julie Krop, and a new commercial chief in charge of maternal health, Audrey Wu. Release

> Hi-Tech Pharmaceuticals agreed to buy supplement maker FormuTech to grow its sports nutrition business. Report

Medical Device News

@FierceMedDev: ICYMI yesterday: Khosla-backed Thync dodges FDA, heads to market with $299 mood-shifting, consumer wearable. Story | Follow @FierceMedDev

@EmilyWFierce: Medtronic forks over $330M to resolve IRS spat. Report | Follow @EmilyWFierce

> St. Jude Medical gets FDA OK to resume trial of Portico TAVR. More

> Calhoun Vision raises $69M for light adjustable intraocular lens FDA approval, launch. Story

> Dexcom, Insulet partner with diabetes data startup Glooko as it expands into insulin pumps, CGMs. Article

Biotech News

@FierceBiotech: ICYMI: Celgene narrows pioneering CAR-T collaboration with bluebird, hands over $25M sweetener.. Report | Follow @FierceBiotech

@JohnCFierce: Promo: Building #Biotech 3.0: The new rules of a changing game. Editor's corner | Follow @JohnCFierce

@DamianFierce: NantCell raised $75M (a month after NantBioScience raised $100M). News | Follow @DamianFierce

> Opko buys up cancer diagnostics player Bio-Reference in $1.47B deal. More

> Active Biotech axes 84% of staff in retreat from R&D. Story

Vaccines News

> Researchers try doctor 'interventions' to boost childhood vax rates. Article

> Merck, Amgen to test Keytruda/T-Vec combo in head and neck cancer. More

> Takeda to consolidate U.S. vaccines ops in Cambridge. Story

> VaxInnate brings seasonal flu vaccine into Phase II. Report

> Celldex's brain cancer vaccine Rintega posts survival edge in PhII. Article

CRO News

> CRO Veristat eyes a roomier HQ after years of growth. Item

> WuXi lands a role in the U.K.'s plot to sequence 100,000 genomes. News

> Quintiles cuts the ribbon on a new Chinese R&D hub. Report

> Recipharm signs on to develop Follicum's hair-growth drug. Article

> AMRI partners up in drug discovery amid a corporate turnaround. Story

Pharma Manufacturing News

> U.S. company gets cGMP certification for Slovenia plant to produce bacteriophages. Article

> DARA to get nanoparticle plant in deal to buy Midatech Pharma. News

> Indian telemarketer of foreign-made drugs goes to federal prison. More

> Indian industry acknowledges some compliance shortcomings, survey finds. Story

> Pozen has a new CEO to deal with the FDA's API concerns. Article

Pharma Asia News

> Takeda consolidates in U.S. amid sharp global vaccine competition. More

> India's NPPA says it really means this deadline on registration. Story

> Celgene's Abraxane denied by India patent office, local generics seen ahead. Article

> Japan aims for high-end drug-device innovation and generics, but will it work? News

> China says papers on MERS candidate to be published soon. Item

And Finally... Bayer CEO Marijn Dekkers visited his MaterialScience operation in Pittsburgh to update workers on plans to spin off that business under the name Covestro and convert to a life-science-focused company. Report

Suggested Articles

A third spinal muscular atrophy treatment option is set to debut with the FDA’s approval for Roche’s Evrysdi, formerly known as risdiplam.

Already developing coronavirus treatments, Takeda struck a licensing deal to manufacture and market Novavax's vaccine candidate in Japan

Pfizer struck a deal to produce Gilead Sciences' remdesivir, which has been running short at some hard-hit U.S. hospitals.